Objective: To determine the frequency of detection of chronic obstructive pulmonary disease (COPD) and Asthma in patients who are admitted to specialized cardiological hospital with arterial hypertension (AH), including AH with chronic heart failure (CHF), coronary heart disease (CHD), cardiac arrhythmias. Analyze the possibility of early diagnosis and the validity of the modified questionnaire for screening risk factors and symptoms of broncho-obstructive pathology in patients with arterial hypertension.Materials and methods: The sample (n = 1000) consisting of individuals over the age of 18 who continuously arrive for inpatient treatment at the admission department of the National Medical Research Center of Cardiology with arterial hypertension, incl. AH with CHF, IHD and arrhythmias in the period from 2018 to 2019. Active identification of broncho-obstructive pathology among all persons was carried out (history taking, complaints), analysis of medical documents provided by patients (conclusions from outpatient and reference cards of the patient), screening of risk factors and symptoms of broncho-obstructive pathology (a modified questionnaire was used), external respiration function was assessed (computer spirometry), filled out the specialized respiratory questionnaires (CAT, mMRC, ACT).Results: The undiagnosed broncho-obstructive diseases was demonstrated against the background of their high occurrence in patients with hypertension, incl. CHF, coronary artery disease, NRS entering a specialized cardiological hospital. The study established the most likely predictors of airway obstruction in patients with hypertension, which signal the need to assess the function of external respiration (computed spirometry).Conclusions: The development and validation of a modified questionnaire makes it possible to identify specific symptoms and risk factors for bronchoobstructive diseases against the backdrop of their high prevalencre among patients who are admitted to cardiology hospital with arterial hypertension.
β-adrenoreceptor (ADRB) ligands are actively used in the therapy of bronchopulmonary and cardiovascular diseases. When using these drugs, it is important to assess changes in ADRB content in different tissues. In most cases, the direct measurement of ADRB content in lung and heart cells is not possible. ADRB2 content in peripheral blood lymphocytes (or mononuclear cells) was shown to correlate with that in myocardial cells. It has been suggested that blood lymphocytes can be used to monitor ADRB content in solid organs. However, the estimation of ADRB1 content in myocardium from its content in peripheral lymphocytes is not possible due to the low content of ADRB1 in lymphocytes. In the present study, we performed simultaneous determination of ADRB1 and ADRB2 both in the total population of PBMCs and in isolated subpopulations of monocytes, T-lymphocytes, and NK-cells from 23 healthy donors using the modified radioligand method. The highest amount of ADRB2 was detected in NK cells, followed by PBMCs, monocytes, and T cells. The content of these receptors in all blood cell subpopulations was significantly correlated with each other, suggesting the possibility of using PBMCs to monitor ADRB2 in solid organs. For the first time, ADRB1 was detected in monocytes and NK cells.
1 March 2019 in Russian Journal of Bioorganic Chemistry
A radioligand-based method was proposed for quantifying the binding activity of β1-adrenergic receptors (ARs) on the surface of human T lymphocytes. Using the transfected HEK293 cell lines...
The management of patients with cardiovascular pathology and comorbid obstructive pulmonary diseases seems to be an urgent problem against the background of their widespread prevalence among the adult population. According to the latest recommendations of GOLD 2017, it is not possible to diagnose COPD and to select options for pharmacotherapy without assessing the symptoms. Evaluation of symptoms in patients with cardiorespiratory pathology is a key element in the diagnosis of both respiratory and cardiovascular deseases. It is important to conduct differential diagnosis of both nosologies for reliable evaluation of the results of standardized respiratory questionnaires. Many respiratory questionnaires have been developed now; some of them have been validated and recommended for use in clinical practice in patients with COPD and asthma. However, their sensitivity and specificity are different, these questionnaires can`t be used interchangeably. In some cases, a decrease in the informative value of standardized respiratory questionnaires was revealed in patients with comorbid cardiovascular and obstructive pulmonary diseases. There are extremely few scientific works, that assess the same aspects of this problem. In connection with this, the development of specialized questionnaires for patients with comorbid cardiovascular and obstructive pulmonary pathology is relevant.
Currently, the increase in comorbid pathology, including patients with bronchoobstructive and cardiovascular diseases remains an urgent problem. Therefore, there is a need not only for new approaches in the tactics of management and treatment of patients with combined cardiorespiratory pathology, but also a more complete understanding of the impact of existing bronchodilator therapy on comorbid pathology and the pathophysiological changes taking place in order to create a new approach to the diagnosis and selection of effective and optimal treatment. The article provides a review of the literature on the impact of beta-2-agonists on pro- and anti-inflammatory mechanisms in patients with bronchial obstruction, including cardiovascular disease.
Background: Comorbid cardiovascular and bronchoobstructive diseases worsens disease course and prognosis and causes difficulties in therapy. Effectiveness 2-agonists (cornerstone of bronchoobstructive pathology treatment) depends on -adrenoreceptors state. Therefore, a detailed study of the functional state of beta-adrenoreceptors is necessary. Aim: to evaluate the relationship of changes in the characteristics of 1- and 2-adrenoreceptors, against the background of the use of 2-agonists in patients with cardiovascular and bronchoobstructive diseases with clinically significant parameters. Methods: In the pilot single-center prospective study during 2.5 years 45 patients (15 with cardiovascular and 30 with bronchoobstructive diseases) were included. Anamnestic data and complaints were collected and laboratory and instrumental studies were performed. Modified radioligand analysis on blood T-lymphocytes using radiolabeled Cyanopindolol and unlabeled selective ligands (ICI 118551, CGP 20712) before and after salbutamol and formoterol was performed and the binding activity of 1- and 2-adrenoreceptors was determined. Results: The correlation analysis between clinically significant parameters and changes in the specific binding index of 1- and 2-adrenoreceptors confirmed its clinical relevance. In test with beta-agonists in cardiovascular and bronchoobstructive diseases patients, an increase in the specific binding index of 1-adrenoreceptors is associated with clinical, laboratory and instrumental parameters of a favorable course of the disease, and an increase in the specific binding index of 2-adrenoreceptors is associated with negative. In the cardiovascular group without bronchoobstructive diseases with salbutamol an increase in the specific binding index of 1-adrenoreceptors was associated with parameters of unfavorable disease course, while an increase in the specific binding index of 2-adrenoreceptors did not have a clear associative relationship with clinical characteristics. Conclusions: The association of changes in the specific binding index of 1- and 2-adrenoreceptors in patients with cardiovascular and bronchoobstructive diseases with clinically significant parameters during acute tests with short- and long-acting 2-agonists was revealed, which in the future may provide an opportunity to identify patients with an unfavorable course of the disease.